U.S. Patent No. 10,117,891 B2 (‘891) issued on November 6, 2018, for “Cannabinoid Composition for Treating Pain.” It was issued to inventors Ramachandra Mukunda of Potomac, Maryland, and Ranga Chelva Krishna of Englewood, New Jersey. The applicant/assignee is India Globalization Capital, Inc., a consolidated multi-industry company with a business division focused on cannabis pharmaceutical research.
The ‘891 claims are directed to a composition for a topical cream consisting of 50-70% by weight tetrahydrocannabinol (THC), 20-40% by weight cannabidiol (CBD), 5-20% by weight cobalamin, or Vitamin B-12, and a carrier. A further limitation is that the THC/CBD is derived from the strain C. sativa. An additional further limitation is that the CBD contains the cannbinoids cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), and various terpenes and flavonoids. The ‘891 specification discloses the topical cream as a treatment for pain including arthritis, herpetic neuralgia, reflex sympathetic dystrophy, and scleroderma, among other pain-associated illnesses.
There were no drawings submitted with the disclosure.
The International Patent Classifications are A61K (preparations for medical, dental purposes, namely medical preparations characterized by special physical form, containing organic active ingredients, or undetermined constitution, e.g., traditional herbal medicines).
This is example of a new inventions focused on medical treatments derived from various cannabis compounds. Therapeutic uses and methods of uses for treatment of pain are popular inventions dealing with cannabis that many companies are seeking patent protection.
Please contact Yonaxis for more information on any of the IP processes described in this posting if you have any questions.